Nociplastic pain

Last updated

Nociplastic pain
Other namesCentral sensitisation (older term)
Widespread Pain Index Areas.svg
Fibromyalgia is the classic example of nociplastic pain, [1] being diagnosed when pain is felt in four different quadrants of the body using measures such as the Widespread Pain Index shown
Specialty Neurology, psychiatry, orthopedics
DurationShort to long-term [2]
Diagnostic method Clinical history, description of pain [3]
Treatment Exercise, medication, psychological therapies, pain neuroscience education [4]

Nociplastic pain, formerly known as central sensitisation, is a term used to describe chronic pain that persists without evidence of tissue injury, resulting in and being sustained by aberrant or heightened pain signal processing of the central nervous system (CNS). [5] It may occur in combination with the other types of pain or in isolation. Its location may be generalised or multifocal, and it can be more intense than would be expected from any associated physical cause. [3]

Contents

The concept and term was formally added to the taxonomy of the International Association for the Study of Pain following the recommendation of a task force in 2017. [6] The root terms are Latin nocēre, meaning to hurt, and Greek πλαστός, meaning development or formation in a medical context.

This type of pain typically arises in some chronic pain conditions, with the archetypal condition being fibromyalgia. Exercise, psychotherapy, and medical therapies are commonly prescribed for such conditions. [7] Nociplastic pain has also been hypothesized to play a role in the persistence of medically unexplained symptoms. [8]

Definition

Nociplastic pain is a longterm complex pain defined by the International Association for the Study of Pain as "pain that arises from altered nociception despite no clear evidence of actual or threatened tissue damage causing the activation of peripheral nociceptors or evidence for disease or lesion of the somatosensory system causing the pain". [2] It is the third proposed mechanism for pain. The other two mechanisms are nociceptive pain and neuropathic pain. [2]

The terms "nociplastic pain" and "central sensitization" are sometimes used interchangeably. However, more recent articles argue that central sensitization is one of the significant mechanisms that contributes to nociplastic pain. [9] Central sensitization is a broader term referring to a hyperexcitability of the nervous system, usually including hyperalgesia (increased sensitivity to pain), and allodynia (painful perception of non-painful stimuli). [8]

Syndromes that are characterized by central nervous system excitability are referred to as central sensitivity syndromes.These include fibromyalgia, irritable bowel syndrome, headaches, chronic fatigue syndrome, and temporomandibular disorder. [10] [11]

Proposed mechanisms

The causes of nociplastic pain are not fully understood and still being investigated, but it is thought to be a dysfunction of the central nervous system whose processing of pain signals may have become distorted or sensitised. [3] There are a variety of proposed mechanisms for nociplastic pain, such as increased integration between parts of the brain responsible for emotion, sensory processing, and attention, increased levels of pain-inciting neurotransmitters, increased immune activity in the central and peripheral nervous system s, and alteration in muscle structure such as the formation of trigger points. [12] Specific central nervous system locations that have been suggested to be the location of the dysfunction are nociceptive neurons, spinal and supraspinal structures, the dorsal horn and others. [8]

There is research suggesting that chronic pain syndromes, such as irritable bowel syndrome, can potentially be triggered by viral illnesses (i.e. COVID-19) or bacterial infections in certain patient populations. It is theorized that infections may increase levels of inflammatory mediators, leading to pain receptor hyper-sensitization and the development of nociplastic pain. However, more research is needed to explore and confirm the link between infections and chronic pain development as much of the data is self-reported. [13] [14]

Presentation

Nociplastic pain is characterized by pain that is isolated to one bodily region or widespread to several bodily regions, along with a poor response to conventional pain-killers. [3] The painful area(s) may experience pain out of proportion to temperature stimuli and applied pressure. There may be CNS-associated symptoms, such as tiredness, difficulties with memory, mood disturbances, and sleep disturbances. [3] It can occur on its own in conditions such as tension headache or fibromyalgia, or combined with other pain categories such as in chronic back pain. [3]

Diagnosis

Tools to measure central sensitization include sensory tests to painful stimuli, magnetic resonance imaging and measures of cytokines and neurotrophines in the blood and urine. [8] Self-report questionnaires such as the Central Sensitization Inventory and the Sensory Hypersensitivity Scale are also used. [15] [16] [8]

Treatment

The treatment of nociplastic pain is often multifaceted. Treatment generally requires both physical and psychological therapies, pain neuroscience education, and sometimes pharmacological therapy. [4] [5]

There are multiple modalities of non-pharmacological treatment available that can help manage nociplastic pain. Exercise is commonly recommended because regular exercise increases the release of mood-elevating neurotransmitters and decreases inflammatory cells in the central nervous system. [5] Transcutaneous electrical nerve stimulation (TENS) also helps to reduce pain by acting on inhibitory spinal cord receptors and activating pain-reducing receptors in the brain. [5] Psychotherapy can also help patients with nociplastic pain to retrain their interpretation of and reaction to pain, improving quality of life. [17]

Pharmacological treatment of nociplastic pain remains complex. Conventional pain management medications such as NSAIDs and opioids have shown limited usefulness in managing nociplastic pain. Currently, SNRI and TCA antidepressants are recommended, but their utility in managing this condition remains unclear. [17]

References

  1. ↑ Chimenti RL, Frey-Law LA, Sluka KA (May 2018). "A Mechanism-Based Approach to Physical Therapist Management of Pain". Physical Therapy. 98 (5): 302–314. doi:10.1093/ptj/pzy030. PMC   6256939 . PMID   29669091.
  2. 1 2 3 Wåhlén K (2020). "Introduction: chronic pain". The pain profile in fibromyalgia: Painomic studies of pain characteristics and proteins in blood. Sweden: Linköping University. p. 9. ISBN   978-91-7929-783-1.
  3. 1 2 3 4 5 6 Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W (May 2021). "Nociplastic pain: towards an understanding of prevalent pain conditions". Lancet. 397 (10289): 2098–2110. doi:10.1016/S0140-6736(21)00392-5. PMID   34062144. S2CID   235245552.
  4. 1 2 Zafereo J (2020). "17. Physical therapy for pain management". In Noe CE (ed.). Pain Management for Clinicians: A Guide to Assessment and Treatment. Switzerland: Springer. pp. 445–448. ISBN   978-3-030-39982-5.
  5. 1 2 3 4 Narale K (8 February 2024). "Nociplastic Pain". Physio-Pedia. Retrieved 12 March 2025.
  6. ↑ IASP Council Adopts Task Force Recommendation for Third Mechanistic Descriptor of Pain, International Association for the Study of Pain, 14 November 2017, archived from the original on 28 June 2021
  7. ↑ Ferro Moura Franco K, Lenoir D, Dos Santos Franco YR, Jandre Reis FJ, Nunes Cabral CM, Meeus M (January 2021). "Prescription of exercises for the treatment of chronic pain along the continuum of nociplastic pain: A systematic review with meta-analysis" (PDF). European Journal of Pain. 25 (1): 51–70. doi:10.1002/ejp.1666. hdl: 10067/1726510151162165141 . PMID   32976664. S2CID   221937920.
  8. 1 2 3 4 5 den Boer C, Dries L, Terluin B, van der Wouden JC, Blankenstein AH, van Wilgen CP, et al. (February 2019). "Central sensitization in chronic pain and medically unexplained symptom research: A systematic review of definitions, operationalizations and measurement instruments". Journal of Psychosomatic Research. 117: 32–40. doi:10.1016/j.jpsychores.2018.12.010. PMID   30665594. S2CID   58565532.
  9. ↑ Nijs J, Malfliet A, Nishigami T (2023). "Nociplastic pain and central sensitization in patients with chronic pain conditions: a terminology update for clinicians". Brazilian Journal of Physical Therapy. 27 (3): 100518. doi:10.1016/j.bjpt.2023.100518. PMC   10314229 . PMID   37348359.
  10. ↑ Yunus MB (June 2007). "Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes". Seminars in Arthritis and Rheumatism. 36 (6): 339–356. doi:10.1016/j.semarthrit.2006.12.009. PMID   17350675.
  11. ↑ Mezhov V, Guymer E, Littlejohn G (December 2021). "Central sensitivity and fibromyalgia". Internal Medicine Journal. 51 (12): 1990–1998. doi: 10.1111/imj.15430 . PMID   34139045. S2CID   235471910.
  12. ↑ Yoo YM, Kim KH (2024-04-01). "Current understanding of nociplastic pain". The Korean Journal of Pain. 37 (2): 107–118. doi:10.3344/kjp.23326. ISSN   2005-9159. PMC   10985487 . PMID   38504389.
  13. ↑ Clauw DJ, Häuser W, Cohen SP, Fitzcharles MA (Aug 2020). "Considering the potential for an increase in chronic pain after the COVID-19 pandemic". Pain . 161 (8): 1694–1697. doi:10.1097/j.pain.0000000000001950. ISSN   0304-3959. PMC   7302093 . PMID   32701829.
  14. ↑ Fernández-de-Las-Peñas C, Nijs J, Neblett R, Polli A, Moens M, Goudman L, et al. (2022-10-13). "Phenotyping Post-COVID Pain as a Nociceptive, Neuropathic, or Nociplastic Pain Condition". Biomedicines. 10 (10): 2562. doi: 10.3390/biomedicines10102562 . ISSN   2227-9059. PMC   9599440 . PMID   36289827.
  15. ↑ Scerbo T, Colasurdo J, Dunn S, Unger J, Nijs J, Cook C (April 2018). "Measurement Properties of the Central Sensitization Inventory: A Systematic Review". Pain Practice. 18 (4): 544–554. doi: 10.1111/papr.12636 . PMID   28851012. S2CID   206247498.
  16. ↑ Dixon EA, Benham G, Sturgeon JA, Mackey S, Johnson KA, Younger J (June 2016). "Development of the Sensory Hypersensitivity Scale (SHS): a self-report tool for assessing sensitivity to sensory stimuli". Journal of Behavioral Medicine. 39 (3): 537–550. doi:10.1007/s10865-016-9720-3. PMC   4854764 . PMID   26873609.
  17. 1 2 Ablin JN (September 2024). "Nociplastic Pain: A Critical Paradigm for Multidisciplinary Recognition and Management". Journal of Clinical Medicine. 13 (19): 5741. doi: 10.3390/jcm13195741 . PMC   11476668 . PMID   39407801.
  18. Clauw DJ, Häuser W, Cohen SP, Fitzcharles MA (August 2020). "Considering the potential for an increase in chronic pain after the COVID-19 pandemic". Pain. 161 (8): 1694–1697. doi:10.1097/j.pain.0000000000001950. PMC   7302093 . PMID   32701829.
  19. Fernández-de-Las-Peñas C, Nijs J, Neblett R, Polli A, Moens M, Goudman L, et al. (October 2022). "Phenotyping Post-COVID Pain as a Nociceptive, Neuropathic, or Nociplastic Pain Condition". Biomedicines. 10 (10): 2562. doi: 10.3390/biomedicines10102562 . PMC   9599440 . PMID   36289827.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.